• Pfizer's 2Q Revenues Up 92% contractpharma
    July 30, 2021
    COVID-19 vaccine BNT162b2 contributes $7.8 billion in sales and alliance revenues.
  • Bristol Myers Squibb revenues increase in Q1 2021 pharmaceutical-technology
    May 06, 2021
    Bristol Myers Squibb has reported revenues of $11.1bn for the first quarter of this year, which represents an increase of 3%, compared to $10.78bn in the first quarter last year.
  • Pfizer 1Q Revenues up 45% Driven by COVID Vax contractpharma
    May 06, 2021
    Vaccine sales were $4.9 billion in the quarter, with BNT162b2 contributing $3.5 billion in global revenues.
  • Financial Report: Amgen contractpharma
    November 06, 2020
    Revenues up 12% in the quarter to $6.4 billion.
  • Financial Report; Abbvie contractpharma
    November 02, 2020
    Revenue up 52% in the quarter to $12.9 billion.
  • Financial Report: PPD contractpharma
    October 30, 2020
    Comments: Clinical Development Services revenue was $1.0 billion in the quarter, up 19% and Laboratory Services revenue was $225.2 million, up 27%.
  • Financial Report: Gilead contractpharma
    October 29, 2020
    Comments: HIV Product sales were $4.5 billion, up 8% primarily due to the continued strength of the HIV franchise and Biktarvy share continues to grow in the U.S. HCV Product sales declined 31% to $464 million impacted by delayed patient starts due to ...
  • Financial Report; Lilly contractpharma
    October 29, 2020
    Comments: Key growth products launched since 2014, consisting of Taltz, Trulicity, Verzenio, Jardiance, Olumiant, Emgality, Tyvyt, Baqsimi, Cyramza, Retevmo and Basaglar contributed nearly 9 percentage points of revenue growth and represented ...
  • Financial Report: Biogen contractpharma
    October 28, 2020
    Commetns: Multiple sclerosis revenues, including $272 million in royalties on sales of OCREVUS, decreased 4%. Total Interferon sales (AVONEX and PLEGRIDY) were down 11% to $474 million.
  • Financial Report, Pfizer contractpharma
    August 13, 2020
    Biopharma revenues were $9.8 billion, up 6% operationally, primarily driven by Vyndaqel.
PharmaSources Customer Service